Leads to Development (L2D) is an R&D company that manages the development of lead compounds for both its clients and its own programmes, from initial non-clinical proof of concept through to phase I clinical trials. Outsourcing this highly specialised non-clinical phase of drug development to L2D allows investors and R&D companies to reach clinical phase I milestones faster, therefore building company value rapidly and cost-effectively.
L2D designs optimal and customized development plans based on its clients’ scientific and business objectives. Validated plans are then implemented, managed and completed by L2D through to and including submission of the clinical trial applications.
L2D was created in 2009 and leverages the considerable scientific, project management, business and regulatory expertise of its founders, particularly in the areas of oncology, neurology and diabetes. The founders have a proven international track record in the biotech R&D arena, and significant experience with small molecules, cell/gene therapies and biologicals.
www.LeadsToDevelopment.com